<table>
<thead>
<tr>
<th>Candidate</th>
<th>Indication</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Phase 2/3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toca 511 &amp; Toca FC</td>
<td>Recurrent high grade glioma</td>
<td>TOCA 5</td>
<td>1Q 2017: Fully enrolled</td>
<td>1H 2018: Report topline data</td>
</tr>
<tr>
<td></td>
<td>Metastatic solid tumors (CRC, RCC, Melanoma, Pancreatic, Lung &amp; Breast)</td>
<td>TOCA 6</td>
<td>2H 2017: Expect preliminary drug activity</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Newly diagnosed high grade glioma</td>
<td>TOCA 7</td>
<td>2018: Initiate Phase 1b</td>
<td></td>
</tr>
</tbody>
</table>